Please login to the form below
Indian variant
This page shows the latest Indian variant news and features for those working in and with pharma, biotech and healthcare.
Pfizer/BioNTech, AZ vaccines effective against Delta COVID-19 variant after two doses
Pfizer/BioNTech and AZ vaccines found to be 96% and 92% effective against variant, respectively. ... Delta variant (previously known as the Indian variant).
Latest news
-
AZ, Pfizer/BioNTech COVID-19 vaccines 'highly effective' against Indian variant
A UK study has found that two doses of either the AstraZeneca or Pfizer/BioNTech COVID-19 vaccines are ‘highly effective’ against the recently identified Indian variant, B.1.617.2. ... In addition, AZ's vaccine was 60% effective against symptomatic
-
WHO director-general says pandemic can be brought under control within months
In particular, the Indian variant – also known as B.1.617 – has some ‘potentially’ important mutations that could help it escape some immunity. ... According to Susan Hopkins of Public Health England, there is not yet enough data to classify the
More from news
Approximately 1 fully matching, plus 2 partially matching documents found.
Subscribe to our email news alerts
- Strategy Director - Healthcare Advertising
- Highly competitive salary
-
Pharmacovigilance Project Lead
- Highly competitive salary
-
Pharmacovigilance Manager
- Highly competitive salary
- Associate Director - Global Healthcare Consulting
- Highly competitive salary
-
Technical Sales Representative
- Highly competitive salary
-
Senior Medical Writer
- Highly competitive salary
- Early Access Program - Regulatory Affairs (EAP-RA)
- Highly competitive salary
-
Omnichannel Account Director
- £55,000 - £65,000 yearly
- Roche and Eli Lilly to collaborate on Alzheimer’s disease blood test
- MHRA to introduce new UK clinical trials framework
- Novo Nordisk suspended from ABPI over ‘serious’ code of practice breaches
- 2023 PM Society Awards – winners announced
- Pfizer pays Royalty Pharma $475m following US approval of migraine nasal spray
- Pfizer and Astellas’ Xtandi shows promise in phase 3 prostate cancer study
- AstraZeneca/MSD’s Lynparza combination approved in UK for prostate cancer
- WHO report highlights impact of COVID-19 pandemic on non-communicable diseases
- Critical success factors and the increasing value of rare disease clinical trials
- Quantum Computing, Artificial Intelligence, & Machine Learning for Drug Discovery
- Novo Nordisk and Dewpoint partner on insulin resistance drug candidates
- AbbVie’s Parkinson’s disease therapy application rejected by FDA
- Team ITG appoints Gerhard Arnhofer as head of customer strategy for life sciences division
- Locus Biosciences announces first patient treated in urinary tract infection trial
- Pfizer pays Royalty Pharma $475m following US approval of migraine nasal spray
- Biogen and Eisai’s Alzheimer’s drug to be covered by US Veterans Health Administration
- VR/AR Applications for Training and Healthcare
Latest intelligence
- Rare diseases: not so rare after all
- The brave new world addressing rare diseases – a way ahead to better and more inclusive treatment...
- Webinar: Evolving Patient Journeys - How to generate deeper insights in a changing healthcare landscape
- Register now for part one in a series, Evolving Patient Journeys, in which our experts look at the main ways in which the patient journey has evolved in recent years....
- DIGITAL EXPERIENCES: LEARNINGS FROM OUTSIDE PHARMA
- It’s long been the case that pharma lags behind other industries when it comes to digital adoption and engagement. So, what can we learn from these other industries, and how...
